Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress toward improved outcomes in haemophilia A, lymphoma, and multiple myeloma Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annua ...

Core Insights - AIM ImmunoTech Inc. has been granted a European patent for its proprietary dsRNA compositions aimed at treating Long COVID, specifically covering Ampligen (rintatolimod) [1] - The company is focused on advancing its pancreatic cancer clinical program while the new patent enhances its intellectual property portfolio and validates Ampligen's potential as a broad-spectrum immunotherapy [2] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company dedicated to developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The lead product, Ampligen, is a first-in-class investigational drug that acts as a dsRNA and TLR3 agonist, demonstrating broad-spectrum activity in clinical trials [4] Clinical Research and Development - Ampligen has shown a broad-spectrum, early-onset antiviral effect by stimulating a strong innate immune response, with data indicating significant decreases in viral replication in SARS-CoV-1 studies [3] - A Phase 2 study (AMP-518) has reported positive topline results, suggesting that Ampligen is generally well tolerated and may reduce fatigue in patients with Long COVID [3]

DEADLINE: November 17, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/cytokinetics-incorporated-loss-submission- form/?id=174892&from=4 Accessibility StatementSkip Navigation NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of CYTK during the class period listed are encouraged t ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of aTyr Pharma, Inc. (NASDAQ: ATYR). Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/atyr-pharma-inc-loss-submission-form/?id=17489 ...

Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other or... ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting today, Monday, November 3rd, at 09:45am ET at the Spartan Capital Investor Conference 2025 in New York City. Event Information: Event NanoViricides Presentation at the Spartan Capital Investor Conference - 2025, New York, NY Track 2 Date Monday, N ...

ORLADEYO Performance and Outlook - ORLADEYO revenue continues strong growth, with a 37% year-over-year increase in Q3 2025[15] - The FY25 guidance range for ORLADEYO revenue has been raised to $590-600 million[17] - Market research reaffirms a strong outlook for ORLADEYO, with an estimated patient LTP share of 24% in 2034[19] - BioCryst anticipates a sustainable $1 billion peak revenue opportunity for ORLADEYO, with a contribution margin exceeding 80%[14] Astria Acquisition and HAE Portfolio Expansion - BioCryst is set to acquire Astria for approximately $700 million TEV, aiming to strengthen its presence in the HAE market[30] - The acquisition is expected to transform BioCryst's revenue profile, projecting a 10+ year double-digit portfolio CAGR[30] - Post-transaction, BioCryst anticipates maintaining profitability (non-GAAP) and positive cash flow[31] - By 2029, the company expects a cash balance of over $1 billion, providing flexibility for future growth opportunities[32] Pipeline Development - Navenibart presents an opportunity to target 5,000+ patients in the US[34] - BCX17725, a targeted KLK5 inhibitor, is under development for Netherton syndrome, with initial Phase 1 data expected by the end of Q1 2026[59]

Accessibility StatementSkip Navigation more press release views with Request a Demo Also from this source Cardinal Health launches a new all-in-one solution for deep vein thrombosis and pulmonary embolism prevention Cardinal Health has announced the international launch of its Kendall SCD SmartFlowâ"¢ Compression System, the next generation of the Kendallâ"¢... Adds the country's leading urology MSO with over 750 providers to Cardinal Health's leading multi-specialty MSO platform, The Specialty Alliance an ...

120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced several milestones in its ORCA-OL long-term safet ...

DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce the robust efficacy of VASCEPA®/VAZKEPA® (icosapent ethyl) in cardiovascular risk reduction (CVRR) as well as highl ...